Innovus Pharma Receives Product License Approval Of Ejectdelay™ For Premature Ejaculation From Health Canada

Published: Dec 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company received the approval of its product license for its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay™ in Canada.

Help employers find you! Check out all the jobs and post your resume.

Back to news